Viewing nowValsartan Film-Coated Tablets 80mg (Valsartan)
Valsartan 80mg
Tablet · Prescription medication
Dongkwang Pharmaceutical Co., Ltd.

MFDS item code 200804093 · Notified 2008.04.14 · Insurance code 645903700
Treatment of essential hypertension, reduction of the risk of death after myocardial infarction, and treatment of heart failure
This drug is mainly used for the treatment of essential hypertension and heart failure in patients intolerant to ACE inhibitors. It also helps to reduce the risk of death in patients with left ventricular dysfunction after myocardial infarction. In other words, it effectively controls hypertension, improves cardiac function, and prevents cardiovascular complications. Due to these effects, it significantly helps manage overall heart health for patients. This drug is used for essential hypertension, heart failure, and reducing mortality risk after myocardial infarction.
1. Essential hypertension Take with water during or between meals. It is recommended to take the drug at the same time each day, if possible (e.g., in the morning). 1) Adults: Regardless of sex or race, the recommended dose is 80 mg of valsartan orally once daily. The blood pressure-lowering effect develops gradually within 2 weeks and reaches its maximum after 4 weeks. For patients whose blood pressure is not adequately controlled, the dose may be increased to 160 mg once daily or a diuretic may be administered concomitantly. If further blood pressure reduction is required, the dose may be increased to a maximum of 320 mg daily. 2) Elderly patients (75 years or older): Start treatment with 40 mg of this drug once daily. 3) Patients with renal impairment: (1) Creatinine clearance 20 ∼ 50 mL/min: No dose adjustment is necessary. (2) Creatinine clearance 10 ∼ 20 mL/min: Start treatment with 40 mg of this drug once daily. (3) Creatinine clearance below 10 mL/min and patients on dialysis: Do not administer this drug. 4) Patients with reduced intravascular volume: For patients with reduced intravascular volume (e.g., patients taking high-dose diuretics whose dose cannot be reduced), start treatment with 40 mg of this drug once daily. 5) Patients with hepatic impairment: In patients with mild or moderate hepatic impairment, start treatment with 40 mg of this drug once daily, and do not exceed 80 mg daily. Do not administer this drug to patients with severe hepatic impairment, cirrhosis, or cholestasis. 2. Heart failure Adults: The recommended starting dose is 40 mg of this drug orally twice daily. The dose may be increased to 80 mg or 160 mg per dose. When administered concomitantly with a diuretic, a reduction in the diuretic dose should be considered. The maximum daily dose is 320 mg, given in divided doses. Triple combination therapy of this drug with an ACE inhibitor and a beta-blocker is not recommended. 3. Reduction of the risk of death after myocardial infarction Adults: Treatment may be started within 12 hours of the onset of myocardial infarction. The recommended starting dose is 20 mg of this drug twice daily. Over the following weeks, the dose may be increased, depending on the patient's tolerability, to 40 mg, 80 mg, and 160 mg per dose twice daily. Consider dose reduction if symptoms of hypotension or renal failure occur. This drug may also be administered to patients receiving other treatments after myocardial infarction (e.g., thrombolytic agents, acetylsalicylic acid, beta-blockers, and statins). However, concomitant administration with an ACE inhibitor is not recommended. 4. Patients with renal impairment: No dose adjustment is necessary if creatinine clearance is 10 mL/min or higher. However, experience with use in patients with creatinine clearance below 10 mL/min or in patients on dialysis is lacking; do not administer this drug to these patients. 5. Patients with hepatic impairment: In patients with mild or moderate hepatic impairment, the daily dose of this drug should preferably not exceed 80 mg. If administering 80 mg or more daily, consider whether the benefits of treatment outweigh the risks when increasing the dose. Do not administer this drug to patients with severe hepatic impairment, cirrhosis, or cholestasis.
Children and adolescents under 18 years of age: Safety and efficacy have not been established.
This medication can cause serious harm to the fetus and newborn when taken during pregnancy; therefore, it should be discontinued immediately once pregnancy is confirmed. Women who are pregnant or may become pregnant, nursing mothers, and those allergic to this drug or its components should not take it. Patients with severe liver impairment, liver cirrhosis, or biliary obstruction should also not use this medication. Patients with a history of hereditary angioedema or angioedema, severe renal impairment, or certain kidney diseases should avoid this drug. Elderly patients or those with high potassium levels should use this medication cautiously, and it is advisable to limit the daily dose to below 80mg in cases of liver disease. Patients with heart valve disease or related heart issues, as well as those with fluid or sodium depletion, should be cautious due to the risk of hypotension. Patients with renal artery stenosis or those recovering from heart failure or myocardial infarction are at risk for worsening kidney function and should have regular kidney function tests. It is advisable not to take this medication within 24 hours before surgery. Due to its strong blood pressure-lowering effects, dizziness or fainting risks exist; caution should be taken when driving or operating machinery. This drug contains specific dyes (Yellow No. 4), so those allergic to them should use it carefully. Taking this drug with potassium-sparing diuretics, potassium supplements, or potassium-containing medications can lead to dangerously high potassium levels in the blood; caution is needed. Taking with nonsteroidal anti-inflammatory drugs (NSAIDs) can reduce the blood pressure-lowering effect and worsen kidney function, especially in the elderly or those with fluid depletion. When taken with lithium preparations, lithium levels may rise, resulting in toxicity, so blood levels should be monitored closely. An overdose of this drug can lead to severe hypotension, decreased consciousness, shock, etc., and immediate medical attention is required in such cases. Keep out of reach of children, and avoid transferring the medication to other containers. It is advisable for pregnant and nursing mothers to avoid taking this drug, and if it must be taken, they should consult a physician.
Not everyone experiences these, and they can vary from person to person.
This medication is sensitive to air and moisture, so it should be stored in a sealed container. Furthermore, it should be kept in a cool place below 30 degrees Celsius to maintain its efficacy.
Soft red circular film-coated tablet
30 tablets/bottle, 300 tablets/bottle
Even with the same ingredient, strength, dosage form and how it is taken can differ.
Viewing nowValsartan 80mg
Tablet · Prescription medication
Dongkwang Pharmaceutical Co., Ltd.

Valsartan 80mg
Tablet · Prescription medication
Novartis Korea Co., Ltd.

Valsartan 160mg
Tablet · Prescription medication
Novartis Korea Co., Ltd.

Valsartan 40mg
Tablet · Prescription medication
Samsung Novartis Co., Ltd.
Valsartan
Prescription medication
Korea Sandos Co., Ltd.
Valsartan
Prescription medication
Korea Sandos Co., Ltd.

Valsartan
Prescription medication
Korea Sandos Co., Ltd.

Valsartan 320mg
Tablet · Prescription medication
Novartis Korea Co., Ltd.
Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.
No questions yet.
For anything that needs medical judgment, consult a doctor or pharmacist.
This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.